NCT00301093View on ClinicalTrials.gov

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

September 10, 2020

Conditions
Leukemia
Interventions
BIOLOGICAL

GM-K562 cell vaccine

Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations

DRUG

imatinib mesylate

Participants will continue on current dose

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00301093 - Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter